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A B S T R A C T
Mesalamine has been successfully used as amaintenance treatment in inﬂammatory bowel diseases such
as ulcerative colitis and Crohn’s disease for years. Most frequent adverse reactions to this medication are
gastrointestinal disorders and headaches while cardiovascular complications are rare and poorly
understood.We present a case of a 26-year-oldmale with ulcerative colitis developingmyopericarditis on
mesalamine therapy. Although cardiac involvement is reported to be an extraintestinal manifestation of
the bowel disease,we describe evidence conﬁrming thediagnosis ofmesalamine-inducedmyopericarditis
inourpatient anddiscussother reports on this topic. Eventhoughmyopericarditis is anuncommonadverse
reaction tomesalamine, it should be considered in patientswith chest pain duringmesalamine therapy. In
such cases, drug withdrawal may result in rapid clinical improvement.
<Learning objective: Mesalamine therapy of inﬂammatory bowel disease (IBD) can be connected with
common adverse reactions such as headaches and gastrointestinal problems. Cardiovascular
complications in patients with IBD may be associated with the disease but may also occur due to
mesalamine therapy. Drug cessation is then sufﬁcient to achieve clinical improvement.>
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.Introduction
Among anti-inﬂammatory drugs used to suppress inﬂammatory
bowel diseases (IBD) such as ulcerative colitis (UC) and Crohn’s
disease, mesalamine (5-aminosalicylic acid, 5-ASA) is a common
agent. Theefﬁcacyof thisnonsteroidal compound isattributed to the
way it interfereswith the cyclooxygenasepathwayand the signaling
pathway of g-form of peroxisomal proliferator-activated receptors,
although the exact mechanisms are not established [1]. The basis of
mesalamine-inducedcardiological adverse reactions is alsonot fully
understood yet. They occur rarely and presentmainly as pericarditis
[2,3], which can be also an extraintestinal manifestation of IBD. We
present a case of myopericarditis in a 26-year-old patient as an
undesirable effect of mesalamine therapy.
Case report
This is a case of a 26-year-old male with 1-month history of UC
diagnosed on the basis of endoscopic and histopathologic results.* Corresponding author at: ul. Liliowa 6/9, 91-864 Lodz, Poland.
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1878-5409/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightHe was initially placed on mesalamine 500 mg three times a day
and prednisone 50 mg per day. Twoweeks after introduction of the
therapy, the patient started to suffer from myalgia, joint pain, and
overall fatigue. Therefore, he decided to discontinue the mesala-
mine treatment.
Drug withdrawal resulted in an exacerbation of the UC that
entailed admission to the Gastroenterology Department where
mesalamine was readministered.
On the third day of mesalamine remedication, the patient
developed acute, stabbing chest pain that intensiﬁed together with
breathing movements. An episode of syncope was also reported.
Body temperature was elevated to 37.3 8C. Initial chest radiograph
and electrocardiogram (ECG) did not reveal any abnormalities
(Fig. 1A). During the following 2 days, the pain did not resolve and
it evolved into a constant feeling of chest pressure and tightness.
Succeeding ECG revealed sinus tachycardia with T-wave inversion
in the limb leads (II, III, aVF) (Fig. 1B). Troponin I concentrationwas
1.218 ng/mL (reference value: 0.0–0.014 ng/mL) and creatine
kinase-MB (CK-MB) concentration was 3.7 ng/mL (reference
value: 0.0–4.0 ng/mL) and they subsequently increased up
to 2.686 ng/mL and 7.4 ng/mL, respectively. Regarding an
elevated D-dimer concentration: 1960.22 ng/mL (reference value:
<500 ng/mL), chest computed tomographic angiography wass reserved.
[(Fig._1)TD$FIG]
Fig. 1. The electrocardiogram course. (A) Off mesalamine (28.11); (B) On mesalamine (01.12); (C) On mesalamine (03.12); (D) Off mesalamine (08.12).
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were negative and no pericardial effusion was detected. At that
moment the patient was sent to our clinic for further evaluation
and treatment.
On admission, he presented with substernal chest pain along
with pulse rate of 115 beats per minute and systolic/diastolic
blood pressure 90/65 mmHg. No other signiﬁcant ﬁndings were
noted. Laboratory tests showed elevated levels of cardiac
enzymes: Troponin T concentration was 164.8 ng/L and peaked
at 232.3 ng/L (reference value: 0.0–14.00 ng/L) and CK-MB
concentration was 37 U/L (reference value 0.0–25.0 U/L). White
blood cell count was 12.04/mL and C-reactive protein (CRP) level
reached 208.6 mg/L.
ECG revealed sinus tachycardia with PQ-segment depression in
the limb leads (II, III, aVF) and ST-segment elevation in the
precordial leads (V2–V6) (Fig. 1C). In order to exclude the diagnosis
of acute coronary syndrome, coronary angiographywas performed
and showed normal coronary vessels. The echocardiographic
evaluation discovered an atrial septal defect with left to right
shunt, but did not conﬁrm either left ventricle systolic dysfunction
or any pericardial effusion (Fig. 3).A diagnosis of myopericarditis was settled based on the
presence of the typical chest pain associated with PQ-segment
depression, ST-segment elevation, and elevated levels of cardiac
enzymes in the absence of coronary artery disease. As mesalamine
seemed to be the most probable cause of this feature, its
administration was ceased. The drug withdrawal resulted in rapid
clinical improvement, resolution of the ST-segment elevation
(Fig. 1D) and decline in cardiac enzymes, WBC count, and CRP level
(Table 1). Within 3-months follow-up since hospital discharge,
there has not been any recurrence of the symptoms.
Discussion
The essence of IBD is gastrointestinal tract involvement but the
disease may manifest in several other organs simultaneously or
independently of the disease activity. Apart from the main
intestinal localization, it seldom affects the cardiovascular system,
but common clinical manifestations include pericarditis, myocar-
ditis, myopericarditis, cardiac tamponade, pericardial effusion,
conductibility disorders, arrhythmias, and systemic thromboem-
bolism [1,2,4,5]. However, settling the diagnosis of extraintestinal
[(Fig._2)TD$FIG]
Fig. 2. Computed tomographic angiography excluded pulmonary embolism.
[(Fig._3)TD$FIG]
Fig. 3. Echocardiogram on admission showed no pericardial effusion.
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exclusion of other possible causes. Most of the reported cases so far
have attributed cardiac symptoms to either an autoimmune
disease associated with bowel disease or an adverse effect of theTable 1 Correlation between clinical data and mesalamine administration.
Date
28.11 1.12 3.12 5.12 8.12
Mesalamine + + +  
Symptoms None Chest pain Chest pain None None
WBC count/mL 9540 12,040 10,800 7600 6000
CRP (mg/L) 26 208.6 154.8 58 17.6
hsTnT (ng/L) – 164.8
232.3
183.2 125.7 83.31
WBC, white blood cell; CRP, C-reactive protein; hsTnT, troponin T.therapy, emphasizing that the exact differentiation is often
difﬁcult to achieve [6,7].
Mesalamine-containing products are reported to cause myo-
and pericarditis. It has not been deﬁnitely established yet whether
5-ASA itself or its derivatives were accountable for cardiac
involvement as it was observed in patients on both types of the
therapy [3,8]. Suggested mechanisms include direct cardiotoxicity
or hypersensitivity reactions type I, III, or IV [3]. Considering the
fact that 5-ASA intake can induce other hypersensitive reactions
involving skin, joints, eyes, and lungs, this mechanism rather than
direct toxicity seems to be themost likely cause. The improvement
obtained after the drug withdrawal and the evident recurrence of
symptoms after its readministration also suggest the above
explanation.
In the current report, we presented a case of a 26-year-old male
developing acute myopericarditis onmesalamine therapy. His ﬁrst
M. Roczek et al. / Journal of Cardiology Cases 10 (2014) 104–107 107symptoms following mesalamine introduction involved joint pains
andmood alteration that could also be speciﬁed as drug side effects
and suggested undesirable reaction to the treatment at its early
stage. All the complaints resolved as soon as the therapywas ceased.
Remedication evoked substernal pain. Its characteristics and
concomitant laboratory test results induced speciﬁc diagnostic
procedures to excludepulmonary embolism.Due to the fact that IBD
is mostly connected with plasmatic hypercoagulation and thus
predisposing to thrombotic events, it seemed essential for ruling out
suchdifferential diagnosis. Further evaluation led to the diagnosis of
pericarditis and suggested mesalamine to be the most probable
cause of the patient’s clinical overall outcome. Elevated levels of
troponin and CK-MBwithout signiﬁcant echocardiographic ﬁndings
indicated slight myocardial injury that did not impair left ventricle
systolic function. Negative coronarography may suggest myocardi-
tis to be responsible for such results. An evident time relation
between occurrence of symptomsand5-ASA intakewas observed in
our case like others previously reported [6,7]. Drug withdrawal was
sufﬁcient toelicit rapidclinical improvement in the cardiac function.
In conclusion, our case reports myopericarditis observed in a
patient with UC on 5-ASA therapy. Although the exactmechanisms
remain unknown, the presented connection between medication
use and cardiac complicationsmakes the diagnosis ofmesalamine-
induced myopericarditis reliable. IBD, especially treated with
mesalamine, should be followed by thoughtful observation and
quick evaluation for possible cardiac injury, regardless of the ﬁnal
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